Ipamorelin vs CJC-1295
Ipamorelin and CJC-1295 are the classical GH-axis research-tool stack pair — a selective GHRP and a long-acting GHRH analogue that engage complementary pituitary GH-release pathways. The two compounds are frequently referenced together in research contexts because their mechanism-of-action angles are synergistic rather than substitutable: combining a ghrelin receptor agonist with a GHRH receptor agonist produces GH-release effects that exceed either compound alone.
At a glance
| Ipamorelin | CJC-1295 | |
|---|---|---|
| Structural class | Pentapeptide GHRP (Growth Hormone Releasing Peptide) | Modified 30-amino-acid GHRH (Growth Hormone Releasing Hormone) analogue |
| Receptor engagement | Ghrelin receptor (GHSR) | GHRH receptor |
| Mechanism-of-action angle | Ghrelin receptor agonism → pituitary GH release, appetite selective | GHRH receptor engagement → sustained GH release (extended half-life) |
| Primary route | Subcutaneous | Subcutaneous |
| Duration of action | Short — dosed 2-3× daily in research protocols | Long — extended half-life via DAC modification (weekly dosing) |
| UK status | No emc entry found (checked 17 October 2026) | No emc entry found (checked 17 October 2026) |
| Signature research application | Selective GH release, GH-axis characterisation | Sustained GH pulse research, GH deficiency modelling |
| Evidence tier | C | C |
Complementary receptor engagement
Ghrelin receptor + GHRH receptor — mechanistically synergistic
Ipamorelin engages the ghrelin receptor (GHSR) on pituitary somatotroph cells, driving GH release through the ghrelin-pathway signalling cascade. The compound's distinctive positioning within the GHRP family is its selectivity — it lacks the cortisol, prolactin, and ACTH release effects associated with earlier GHRPs, providing a cleaner research-tool profile for GH-specific research applications.
CJC-1295 engages the GHRH receptor on pituitary somatotroph cells, driving GH release through the GHRH-pathway signalling cascade. The compound's distinctive positioning is the extended half-life — the DAC (drug affinity complex) modification confers substantial plasma half-life extension over parent GHRH, allowing for weekly rather than daily dosing in the DAC-modified CJC-1295 variant.
The two receptor-engagement pathways are complementary at the pituitary level. Ghrelin-pathway GH release and GHRH-pathway GH release engage distinct intracellular signalling cascades that both terminate in GH secretion. Combining the two mechanisms produces GH-release effects that substantially exceed the effect of either compound alone — the mechanistic basis for the classical Ipamorelin + CJC-1295 stack that dominates GH-axis research protocols.
Cognitive-relevance and safety considerations
GH-axis research context and cognitive-endpoint research angle
The cognitive-relevance research context for these compounds derives from the GH/IGF-1 axis's role in cognitive function. GH-axis activity supports IGF-1 production, and IGF-1 has documented effects on hippocampal neurogenesis, synaptic plasticity, and cognitive-endpoint measures in animal models. This mechanism-of-action framing motivates GH-axis research applications in cognitive-decline and cognitive-ageing research contexts.
Neither compound has a substantial cognitive-endpoint clinical evidence base — they are positioned as GH-axis research tools rather than direct cognitive-endpoint interventions. The cognitive-relevance is indirect, operating through the IGF-1 axis rather than through direct cognitive-effect pharmacology.
Both compounds are listed in section S2.2.4 of the WADA 2026 Prohibited List (prohibited at all times) — any athlete-adjacent research application needs to account for the anti-doping compliance framework. Additional safety considerations include the GH-axis general concerns around insulin sensitivity, glucose regulation, and the theoretical oncological concerns associated with chronic GH-axis activation.